Director/PDMR Shareholding

RNS Number : 9314J

Hikma Pharmaceuticals Plc

16 April 2020

 

Hikma Pharmaceuticals PLC

Notification and public disclosure of transactions by persons discharging managerial responsibilities

Said Darwazah

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Said Darwazah
2	Reason for the notification
a)	Position/status	Executive Chairman
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hikma Pharmaceuticals PLC
b)	LEI	549300BNS685UXH4JI75
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083
b)	Nature of the transaction	Conditional Shares acquired from the grant made on 13 April 2017 and vested on 14 April 2020 under the 2014 EIP Element C.
c)	Price(s) and volume(s)	Price(s): £nil Volume(s): 36,438
d)	Aggregated information	N/A
e)	Date of the transaction	15 April 2020
f)	Place of the transaction	London Stock Exchange (XLON)

Mazen Darwazah

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Mazen Darwazah
2	Reason for the notification
a)	Position/status	Executive Vice Chairman
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hikma Pharmaceuticals PLC
b)	LEI	549300BNS685UXH4JI75
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083
b)	Nature of the transaction	Conditional Shares acquired from the grant made on 13 April 2017 and vested on 14 April 2020 under the 2014 EIP Element C.
c)	Price(s) and volume(s)	Price(s): £nil Volume(s): 19,318
d)	Aggregated information	N/A
e)	Date of the transaction	15 April 2020
f)	Place of the transaction	London Stock Exchange (XLON)

Majda Labadi

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Majda Labadi
2	Reason for the notification
a)	Position/status	PDMR
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hikma Pharmaceuticals PLC
b)	LEI	549300BNS685UXH4JI75
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083
b)	Nature of the transaction	Conditional Shares acquired from the grant made on 13 April 2017 and vested on 14 April 2020 under the 2014 EIP Element C.
c)	Price(s) and volume(s)	Price(s): £nil Volume(s): 16,146
d)	Aggregated information	N/A
e)	Date of the transaction	15 April 2020
f)	Place of the transaction	London Stock Exchange (XLON)

Riad Mishlawi

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Riad Mishlawi
2	Reason for the notification
a)	Position/status	PDMR
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hikma Pharmaceuticals PLC
b)	LEI	549300BNS685UXH4JI75
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083
b)	Nature of the transaction	Conditional Shares acquired from the grant made on 13 April 2017 and vested on 14 April 2020 under the 2014 EIP Element C.
c)	Price(s) and volume(s)	Price(s): £nil Volume(s): 20,146
d)	Aggregated information	N/A
e)	Date of the transaction	15 April 2020
f)	Place of the transaction	London Stock Exchange (XLON)

Bassam Kanaan

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Bassam Kanaan
2	Reason for the notification
a)	Position/status	PDMR
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hikma Pharmaceuticals PLC
b)	LEI	549300BNS685UXH4JI75
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083
b)	Nature of the transaction	Conditional Shares acquired from the grant made on 13 April 2017 and vested on 14 April 2020 under the 2014 EIP Element C.
c)	Price(s) and volume(s)	Price(s): £22.82 Volume(s): 23,233
d)	Aggregated information	Number of Shares: 23,233 Price: £530,177
e)	Date of the transaction	14 April 2020
f)	Place of the transaction	London Stock Exchange (XLON)

Khalid Nabilsi

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Khalid Nabilsi
2	Reason for the notification
a)	Position/status	PDMR
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hikma Pharmaceuticals PLC
b)	LEI	549300BNS685UXH4JI75
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083
b)	Nature of the transaction	Conditional Shares acquired from the grant made on 13 April 2017 and vested on 14 April 2020 under the 2014 EIP Element C.
c)	Price(s) and volume(s)	Price(s): £22.82 Volume(s): 23,751
d)	Aggregated information	Number of Shares: 23,751 Price: £541,998
e)	Date of the transaction	14 April 2020
f)	Place of the transaction	London Stock Exchange (XLON)

Susan Ringdal

a)	Name	Susan Ringdal
2	Reason for the notification
a)	Position/status	PDMR
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hikma Pharmaceuticals PLC
b)	LEI	549300BNS685UXH4JI75
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083
b)	Nature of the transaction	Shares acquired from the exercise of nil-cost options granted on 17 May 2013 and 11 June 2014 under the 2007 LTIP and nil-cost options granted on 10 April 2015 under the 2014 EIP Elements B and C
c)	Price(s) and volume(s)	Share Plan Price Volume 2013 LTIP £22.82 18,424 2014 LTIP £22.82 11,774 2015 EIP B £22.82 6,006 2015 EIP C £22.82 6,006
d)	Aggregated information	Number of Shares: 42,210 Price: £963,232
e)	Date of the transaction	15 April 2020
f)	Place of the transaction	London Stock Exchange (XLON)

Brian Hoffmann

a)	Name	Brian Hoffmann
2	Reason for the notification
a)	Position/status	PDMR
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hikma Pharmaceuticals PLC
b)	LEI	549300BNS685UXH4JI75
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083
b)	Nature of the transaction	Shares acquired from the vesting of nil-cost options granted on 11 May 2016 and 13 April 2017 under the 2014 EIP Element B.
c)	Price(s) and volume(s)	Share Plan Price Volume 2016 EIP B £22.34 8,230 2017 EIP B £22.34 9,327
d)	Aggregated information	Number of Shares: 17,557 Price: £392,223
e)	Date of the transaction	16 April 2020
f)	Place of the transaction	London Stock Exchange (XLON)

a)	Name	Brian Hoffmann
2	Reason for the notification
a)	Position/status	PDMR
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hikma Pharmaceuticals PLC
b)	LEI	549300BNS685UXH4JI75
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083
b)	Nature of the transaction	Disposal of Shares.
c)	Price(s) and volume(s)	Price(s): £22.79 Volume(s): 2,219
d)	Aggregated information	Number of Shares: 2,219 Price: £50,571
e)	Date of the transaction	14 April 2020
f)	Place of the transaction	London Stock Exchange (XLON)

Peter Speirs
Company Secretary, responsible for releasing this announcement
16 April 2020
[phone]

 

END

 

 

DSHBSGDSUGBDGGL